RIVER BIOMEDICS
Desconocido
3DCardiacHTS: Bringing 3D cardiac tissues to high throughput for drug discovery screens
RIVER BIOMEDICS B.V.
tramitó un
HORIZON EUROPE
HORIZON-EIC-2022-TRANSITION-01
1. Cardiovascular disease is the number 1 cause of death worldwide. Novel cardiovascular drugs have a high failure rate of 91% in clinical t...
2022-10-26 - 2025-11-30 | Financiado
2022-10-26 - 2025-11-30 | Financiado
BioRobot-MiniHeart: Engineering a living human Mini-heart and a swimming Bio-robot
RIVER BIOMEDICS B.V.
participó en un
HORIZON EUROPE
HORIZON-EIC-2021-PATHFINDERCHALLENGES-01
Cardiovascular disease (CVD) is still the N1 cause of death worldwide despite the significant efforts of academia and pharmaceutical industr...
2022-06-23 - 2027-10-31 | Financiado
2022-06-23 - 2027-10-31 | Financiado
* No se disponen de datos de la empresa actual.